As AAOS Sees Record Growth in Fracture & Trauma Registry Data Submissions, Technology Partnership Offering with PatientIQ Expands to Include Nationwide Participation Options

On the heels of a successful technology pilot program with PatientIQ, the American Academy of Orthopaedic Surgeons (AAOS) has seen a rapid increase in data submissions to the Fracture & Trauma Registry (FTR). Through the submission and analysis of data to the FTR, healthcare systems and orthopaedic surgeons can actively utilize the knowledge gained to improve outcomes and the quality of orthopaedic care in turn supporting highly informed decision-making and quality improvement.

AAOS partnered with PatientIQ in December 2022 to integrate its cloud-based platform directly with FTR participants’ electronic health records (EHR) and simplify the process to collect and submit registry data for five of the more common fractures in the U.S. Within the first eight months, the partnership yielded a substantial increase in data submitted to the FTR. By expanding the participation options to include the PatientIQ solution, the FTR is reducing barriers to tracking evidence-based practices and advancing the delivery of musculoskeletal care. To date, there are 35 participating sites contributing to the FTR.

Michael J. Gardner, MD, FAAOS,
chair of the AAOS Fracture & Trauma Registry Steering Committee
….

“Due to the complexity of having five modules in one registry, we recognized potential data challenges for some sites. We collaborated with PatientIQ to help mitigate the burden and enhance data submission.Consequently, data within the registry has increased significantly and is helping fuel new momentum within the registry.”

Automating Registry Participation Within a Matter of Weeks
Utilizing FHIR-based APIs and other live integration functionality, PatientIQ can help extract and translate critical health information into registry-compliant specifications and submit it on behalf of participating orthopaedic surgeons. In doing so, the platform eases the administrative and technological burden associated with submitting procedural, post operative and patient-reported outcomes to the FTR.

Click here to watch a webinar discussing one customer’s journey with the FTR Powered by PatientIQ.

Hospital sites, ambulatory service centers or institutions where fracture and trauma-related incidents are treated are invited to participate in the FTR. Enrollment through PatientIQ is encouraged, but optional. To get involved with the FTR, email an AAOS Registry engagement associate at RegistryEngagement@aaos.org, call 847-292-0530, or click here. For more information about PatientIQ, visit www.patientiq.io.

SourceAAOS

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version